Navigation Links
Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
Date:11/8/2007

at Administration (ACR Presentation 309)

The objective of the re-treatment study was to evaluate the safety, PD, PK and immunogenicity of TRU-015 for RA with repeated doses after receiving initial administration in a Phase I/IIa study. Patients treated with a single course of 5 mg/kg or higher in a previously conducted TRU-015 Phase I/IIa study were eligible for re-treatment. Patients who received a single infusion of 5 mg/kg received a single infusion of 5 mg/kg upon re-treatment, and those who received higher doses of TRU-015 received a single infusion of 15 mg/kg upon re-treatment. PD response of B-cells was also evaluated after initial treatment and after re-treatment.

Fifty-four patients were eligible for re-treatment, and at the time of this analysis, re-treatment data were available for 36 patients. B-cell depletion and recovery following re-treatment with TRU-015 was comparable to that seen after initial treatment. Ongoing patient evaluations showed maintenance of ACR responses with repeated single doses of TRU-015 at six-month intervals through at least two retreatment courses. Total serum IgG levels remained within normal limits. In addition, subjects treated with three or more courses of therapy experienced persistent decreases in rheumatoid factor and IgM levels without experiencing decreases in IgG or IgA levels. No neutralizing antibodies to TRU-015 had been detected at the time of this assessment.

Re-treatment with TRU-015 was generally well tolerated, and no grade 3 or 4 adverse events occurred on the day of infusion.

TRU-015 Clinical Development

Trubion and Wyeth have agreed on the design of the next clinical trial, and both companies are working to finalize protocol details and plans for study initiation. The randomized, double-blind, placebo-controlled, multicenter trial will examine ways to further optimize efficacy while evaluating dosing schedule. Additional study protocol details will be provided after commencemen
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... 30, 2015 Future Market Insights ... "Continuous Glucose Monitoring Systems Market: Global Industry Analysis and ... the global continuous glucose monitoring systems market was valued ... to reach US$ 788.4 Mn by 2020, registering a ... 2020. Global continuous glucose monitoring systems market ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... 2011 Zimmer Holdings, Inc. (NYSE: ZMH ; ... the Zimmer NexGen LPS-Flex Mobile Bearing ... the United States.  The LPS-Flex Mobile Bearing knee provides a ... cruciate ligament (ACL), replicating the anatomic center of knee rotation. ...
... Reportlinker.com announces that a new market research ... Merck & Co., Inc.: PharmaVitae Profile ... IntroductionThis analysis examines the historical and forecast performance ... sector. The profile encompasses global company strategy, portfolio ...
Cached Medicine Technology:Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 2Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 3Reportlinker Adds Merck & Co., Inc.: PharmaVitae Profile 2
(Date:8/1/2015)... ... , ... The condition where veins are enlarged and gnarled is known as ... discomfort. Those who spend a lot of time on their feet and standing are ... what it can to create awareness and provide a cure in observance of Senior ...
(Date:8/1/2015)... ... 2015 , ... Brig and Lita Hart, icons of the network marketing industry ... Home mission with the HOPE Movement of EvolvHealth. In what has been a long-term ... agreed to join their missions of purpose together to change the course of the ...
(Date:8/1/2015)... ... ... Lume Wellness creators Alex, Robert, and Sam have announced update 3.0.1 to ... , The app is designed to track various metrics of wellness, including physical activity, ... health and use this information for positive behavior modification. Lume Wellness keeps track of ...
(Date:8/1/2015)... ... ... Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery (CCAR) – began ... and heading north. Since that day, Phil has hiked over 1400 miles in nine states. ... family. He visited CCAR and left an inspirational message to his staff: “You can ...
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... events, from tornados, floods, fires and hurricanes, researchers at ... physiological changes associated with aging and the presence of ... or injury, even death, during a disaster. Investigators ... of 86, who were evacuated for five days due ...
... France, 21 October 2011 A pioneering educational resource, ... chronic hepatitis B, was launched today at an annual ... 26 patient advocacy groups from 14 countries and regions ... ("Patients and Professionals Acting Together for Hepatitis B") programme ...
... FRIDAY, Oct. 21 (HealthDay News) -- Elevated levels of hormones ... number of different elevated hormones rises, so does the risk, ... Women,s Hospital and Harvard Medical School in Boston examined levels ... collected from nurses up to nine years before their health ...
... a higher burden of multiple, large-joint osteoarthritis (OA), and may ... OA." African Americans were also more likely to have knee ... than Caucasians according to the findings reported today in ... College of Rheumatology (ACR). OA is the most ...
... -- The number of American women with precancerous cells ... 2000, and the increase has led to the release Thursday ... Cancer of the vulva -- the outside of the genital ... (HPV), which also causes cervical cancer. The precancerous condition -- ...
... , THURSDAY, Oct. 20 (HealthDay News) -- Most Americans consume ... needed to reduce the amount of dietary salt, according to ... of sodium consumption are associated with increased risk of high ... experts warn. In general, people aged 2 years and ...
Cached Medicine News:Health News:Elderly long-term care residents suffer cognitively during disasters 2Health News:'PATH B,' a comprehensive support program in Europe for patients with chronic hepatitis B launched 2Health News:'PATH B,' a comprehensive support program in Europe for patients with chronic hepatitis B launched 3Health News:Breast Cancer Risk May Rise With High Hormone Levels 2Health News:More African-Americans burdened by osteoarthritis in multiple large joints 2Health News:Rise in Vulvar Precancers Leads to New Guidelines 2Health News:U.S. Diet Still Has Too Much Salt, CDC Warns 2
Cannulated Interference Screws...
Cannulated Interference Screws...
... new WHITESTAR Technology, which transforms traditional ultrasound ... reduces the amount of phaco energy directed ... ultrasound cutting efficiency. Surgeons have ... and efficiently to the phaco tip, in ...
... NATURE'S TEARS is an all-natural moisturizing mist ... assistance of Dr. William Mathers, from Oregon ... Mathers' study of NATURE'S TEARS (2000) and ... the mist doubled the moisture volume of ...
Medicine Products: